Suppr超能文献

MYC免疫组织化学通过荧光原位杂交预测重排。

MYC Immunohistochemistry Predicts Rearrangements by FISH.

作者信息

Nwanze Julum, Siddiqui Momin T, Stevens Keith A, Saxe Debra, Cohen Cynthia

机构信息

Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, United States.

Department of Pathology and Laboratory Medicine, Tulane University Hospital, New Orleans, LA, United States.

出版信息

Front Oncol. 2017 Sep 21;7:209. doi: 10.3389/fonc.2017.00209. eCollection 2017.

Abstract

is the proto-oncogene classically associated with Burkitt lymphoma (BL) located at chromosomal locus 8q24. Rearrangements of are seen in nearly 100% of BL but have been reported in 3-16% of diffuse large B-cell lymphomas (DLBCLs). Rearrangements of are tested for by flourescence hybridization (FISH). In this study, we compared immunohistochemistry (IHC) using a monoclonal antibody directed against the human Myc protein to the current method, FISH. 31 cases were identified that had been tested for rearrangements by FISH over 27 months with heterogeneity in the diagnoses: 5 BL; 10 DLBCL; 3 B-cell lymphoma unclassifiable between DLBCL and BL; 5 B-cell lymphoma not otherwise specified; 1 EBV-related B-cell lymphoma; 1 composite CLL/SLL-large cell lymphoma; and 6 designated as high-grade or aggressive B-cell lymphoma. Analysis by FISH was performed as part of the clinical workup, where a rearrangement is defined as a split fusion signal in at least 5.7% of cells. Myc-IHC was interpreted as a qualitative positive (overexpressed) or negative (not overexpressed) result. 12 cases (39%) were positive for rearrangements by FISH. Overall, 13 cases (42%) showed Myc overexpression by IHC, 11 of which harbored a rearrangement by FISH. There were two false positives and one false negative. Thus, Myc-IHC predicted a rearrangement by FISH with 92% sensitivity and 89% specificity. We can thus conclude that Myc-IHC should be a potentially useful screening tool for identifying lymphomas that may harbor a rearrangement.

摘要

是经典的与位于染色体位点8q24的伯基特淋巴瘤(BL)相关的原癌基因。在几乎100%的BL中可见其重排,但在3%-16%的弥漫性大B细胞淋巴瘤(DLBCL)中也有报道。通过荧光原位杂交(FISH)检测其重排。在本研究中,我们将使用针对人Myc蛋白的单克隆抗体的免疫组织化学(IHC)与当前方法FISH进行了比较。在27个月内通过FISH检测了31例病例的重排,诊断存在异质性:5例BL;10例DLBCL;3例无法在DLBCL和BL之间分类的B细胞淋巴瘤;5例其他未特定说明的B细胞淋巴瘤;1例EBV相关的B细胞淋巴瘤;1例复合性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤-大细胞淋巴瘤;以及6例被指定为高级别或侵袭性B细胞淋巴瘤。FISH分析作为临床检查的一部分进行,其中重排定义为至少5.7%的细胞中出现分裂融合信号。Myc-IHC被解释为定性阳性(过表达)或阴性(未过表达)结果。12例(39%)FISH检测为重排阳性。总体而言,13例(42%)通过IHC显示Myc过表达,其中11例FISH检测存在重排。有2例假阳性和1例假阴性。因此,Myc-IHC预测FISH重排的敏感性为92%,特异性为89%。我们可以得出结论,Myc-IHC应该是一种潜在有用的筛查工具,用于识别可能存在重排的淋巴瘤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/985a/5613089/6cc8d6732a44/fonc-07-00209-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验